BioSpace News Archive

Immune thrombocytopenia is an autoimmune-mediated hematological disorder affecting the platelets. The immune system of the patient with immune thrombocytopenia produces antibodies directed against platelet antigens, causing platelet destruction and suppression of platelet production in the bone marrow cells.

With enhanced efficiency, fast dissolving thin films are gaining significant momentum, creating growth opportunities for oral thin films market

Afimmune, a clinical stage drug discovery company focused on the development of biologically active lipids for the treatment of cardiometabolic diseases, announced key findings with epeleuton from preclinical atherosclerosis studies.

Arvinas, Inc., a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, announced that Ron Peck, M.D., Chief Medical Officer, and Sean Cassidy, Chief Financial Officer, will participate in a fireside chat at the 42nd Annual Goldman Sachs Global Healthcare Conference on Thursday, June 10 at 10:30 a.m. ET.

Algernon Pharmaceuticals Inc. announces it has initiated a new clinical research program for pancreatic cancer and NP-120.

IGM Biosciences Announces Expansion of IgM Platform into Infectious Diseases, Publication of Preclinical Data in Nature Demonstrating Engineered IgM Antibody Antiviral Activity for the Treatment and Prevention of COVID-19

Dr. Chavala is co-founder of CiRC Biosciences with Jeff Aronin, chairman and CEO of Paragon Biosciences.

Protagonist Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for its lead investigational new drug candidate, rusfertide, for the treatment of patients with polycythemia vera (PV)

Synchron, a brain interface platform company , today announced that the company has secured $40M in a eries B round of financing led by Silicon Valley venture capital firm Khosla Ventures.

Kala Pharmaceuticals, Inc., today announced that OptumRx, one of the largest pharmacy benefit managers (PBM) in the United States, has added EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% as a covered brand on its commercial formularies, effective May 21, 2021.